bioAffinity Technologies, Inc. — Director's Dealing 2023

Mar 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-09-06

Reporting Person: Meghji Mohsin Y (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-06	Common Stock, par value $0.007	C	40907	$3.67	Acquired	69478	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-06	Series A Convertible Preferred Stock	$3.67	C	286349	Disposed		Common Stock (40907)	Direct

Footnotes

F1: The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2: In connection with the IPO closing on September 6, 2022, the 286,349 shares of Series A Convertible Preferred Stock owned by Mr. Meghji automatically converted at the then-effective 1 for 7 conversion rate (as adjusted for the Issuer's 1-for-7 reverse stock split) into 40,907 fully paid and nonassessable shares of Common Stock. The Series A Convertible Preferred Stock had no expiration date.